Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer treatments, has announced its participation in the Wedbush PacGrow Healthcare Conference. The event is scheduled for Tuesday, August 13, 2024, at 11 AM ET in New York City.
This conference provides Compass Therapeutics with an opportunity to showcase its progress in developing innovative oncology therapies. As a company dedicated to creating proprietary antibody-based therapeutics for multiple human diseases, Compass's participation in this healthcare conference could offer valuable insights into its current projects and future plans in the biotechnology sector.
Compass Therapeutics (Nasdaq: CMPX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti oncologici basati su anticorpi, ha annunciato la sua partecipazione alla Wedbush PacGrow Healthcare Conference. L'evento si svolgerà martedì 13 agosto 2024, alle 11 AM ET a New York City.
Questa conferenza offre a Compass Therapeutics l'opportunità di mostrare i suoi progressi nello sviluppo di terapie oncologiche innovative. Essendo un'azienda impegnata nella creazione di terapie proprietarie basate su anticorpi per diverse malattie umane, la partecipazione di Compass a questa conferenza sanitaria potrebbe fornire preziose informazioni sui suoi progetti attuali e sui futuri piani nel settore biotecnologico.
Compass Therapeutics (Nasdaq: CMPX), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de tratamientos contra el cáncer basados en anticuerpos, ha anunciado su participación en la Wedbush PacGrow Healthcare Conference. El evento está programado para el martes 13 de agosto de 2024, a las 11 AM ET en la ciudad de Nueva York.
Esta conferencia proporciona a Compass Therapeutics la oportunidad de mostrar su progreso en el desarrollo de terapias oncológicas innovadoras. Como empresa dedicada a crear terapias propietarias basadas en anticuerpos para diversas enfermedades humanas, la participación de Compass en esta conferencia de salud podría ofrecer información valiosa sobre sus proyectos actuales y futuros planes en el sector biotecnológico.
컴파스 테라퓨틱스(나스닥: CMPX)는 항체 기반 암 치료제를 개발하는 임상 단계의 생명공학 회사로, Wedbush PacGrow Healthcare Conference에 참가한다고 발표했습니다. 이 행사는 2024년 8월 13일 화요일, 오전 11시 ET에 뉴욕시에서 열릴 예정입니다.
이번 컨퍼런스는 컴파스 테라퓨틱스에게 혁신적인 종양학 치료법 개발에 대한 진전을 선보일 기회를 제공합니다. 여러 인체 질환에 대한 독자적인 항체 기반 치료제를 개발하는 데 헌신하고 있는 컴파스는 이번 건강 관리 컨퍼런스에 참여함으로써 현재 진행 중인 프로젝트와 생명공학 분야의 미래 계획에 대한 귀중한 통찰력을 제공할 수 있습니다.
Compass Therapeutics (Nasdaq: CMPX), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de traitements anticorps contre le cancer, a annoncé sa participation à la Wedbush PacGrow Healthcare Conference. L'événement est prévu pour mardi 13 août 2024, à 11h ET à New York.
Cette conférence offre à Compass Therapeutics l'opportunité de présenter ses avancées dans le développement de thérapies oncologiques innovantes. En tant qu'entreprise dédiée à la création de thérapeutiques basées sur des anticorps pour diverses maladies humaines, la participation de Compass à cette conférence sur la santé pourrait fournir des informations précieuses sur ses projets actuels et ses plans futurs dans le secteur de la biotechnologie.
Compass Therapeutics (Nasdaq: CMPX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von antikörperbasierten Krebsbehandlungen konzentriert, hat seine Teilnahme an der Wedbush PacGrow Healthcare Conference angekündigt. Die Veranstaltung findet am Dienstag, den 13. August 2024, um 11 Uhr ET in New York City statt.
Diese Konferenz bietet Compass Therapeutics die Möglichkeit, seine Fortschritte bei der Entwicklung innovativer Onkologie-Therapien zu präsentieren. Als Unternehmen, das sich der Schaffung proprietärer antikörperbasierter Therapeutika für verschiedene menschliche Krankheiten widmet, könnte die Teilnahme von Compass an dieser Gesundheitskonferenz wertvolle Einblicke in aktuelle Projekte und zukünftige Pläne im Biotechnologiesektor bieten.
- None.
- None.
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
When and where is Compass Therapeutics (CMPX) presenting at the Wedbush PacGrow Healthcare Conference?
What type of company is Compass Therapeutics (CMPX)?
What is the focus of Compass Therapeutics' (CMPX) research and development?
What stock exchange is Compass Therapeutics (CMPX) listed on?
